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Abstract
Objective
In order to search for metabolic biomarkers of antihypertensive drug responsiveness, we
measured >600 biochemicals in plasma samples of subjects participating in the GENRES
Study. Hypertensive men received in a double-blind rotational fashion amlodipine, bisopro-
lol, hydrochlorothiazide and losartan, each as a monotherapy for one month, with interven-
ing one-month placebo cycles.
Methods
Metabolomic analysis was carried out using ultra high performance liquid chromatography-
tandem mass spectrometry. Full metabolomic signatures (the drug cycles and the mean of
the 3 placebo cycles) became available in 38 to 42 patients for each drug. Blood pressure
was monitored by 24-h recordings.
Results
Amlodipine (P values down to 0.002), bisoprolol (P values down to 2 x 10−5) and losartan
(P values down to 2 x 10−4) consistently decreased the circulating levels of long-chain acyl-
carnitines. Bisoprolol tended to decrease (P values down to 0.002) the levels of several
medium- and long-chain fatty acids. Hydrochlorothiazide administration was associated
with an increase of plasma uric acid level (P = 5 x 10-4) and urea cycle metabolites.
Decreases of both systolic (P = 0.06) and diastolic (P = 0.04) blood pressure after amlodi-
pine administration tended to associate with a decrease of plasma hexadecanedioate, a
dicarboxylic fatty acid recently linked to blood pressure regulation.
Conclusions
Although this systematic metabolomics study failed to identify circulating metabolites con-
vincingly predicting favorable antihypertensive response to four different drug classes, it
provided accumulating evidence linking fatty acid metabolism to human hypertension.
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Introduction
In view of the facts that elevated blood pressure has evolved as the leading contributor to global
burden of disease [1,2] and unsatisfactory control rates achieved by antihypertensive drug
treatment [3,4], there is an urgent need for more effective ways to individualize drug therapies
in a patient-specific fashion. While pharmacogenomics approaches may be well suited for per-
sonalized treatment of the rare varieties of monogenic hypertension [5,6], studies on pharma-
cogenomics of essential hypertension have shown much less progress [7,8]. Recent genome-
wide association studies on genetic associations of specific antihypertensive drug responses
have revealed several potential gene loci of interest [9–16], but the data so far published have
lacked consistently replicated findings, and presently there appears to be no clinically useful
genetic markers to guide the choice of a given blood pressure-lowering drug.
Metabolomics has been widely used to address a number of questions in human health and
disease and has recently been introduced in studies of human hypertension (for review, see
[17]). As the first steps toward pharmacometabolomics of hypertension, Wikoff et al. [18],
Rotroff et al. [19] and Shahin et al. [20] have identified sets of blood metabolites associated
with blood pressure lowering in response to atenolol or hydrochlorothiazide. In addition,
using two independent population samples, each amounting appr. 1500 subjects, Menni et al.
[21] identified a novel pathway involving hexadecanedioate as an important regulator of
human blood pressure. In addition, high serum hexadecanedioate levels were associated with
elevated systolic and diastolic blood pressure levels in both European-American and African-
American populations [22].
In order to systematically characterize the effects of different classes of antihypertensive
drugs on the circulating metabolic profile, we have taken advantage of our GENRES (Genetics
of Drug Responsiveness in Essential Hypertension) Study platform [13,23] in which we have
studied, in a placebo-controlled, cross-over fashion, the antihypertensive effects of four differ-
ent drugs (a diuretic, a beta blocker, a calcium channel blocker and an angiotensin receptor
antagonist). This rotational study design permits the assessment of the effects of the different
drug classes on plasma metabolic profiles in the same individuals, and the use of integrated
baseline values derived from three different intervening placebo cycles provides a further
means to reduce experimental variation.
Materials and methods
Design of the GENRES study: Patients, drug treatments and blood
pressure measurements
The design and principal results of the GENRES Study have been published previously
[13,23,24]. In brief, a total of 313 hypertensive Finnish men (aged 35 to 60 years) were initially
recruited. Inclusion criteria were diastolic blood pressure95 mmHg in repeated measure-
ments or use of antihypertensive medication. Each study participant received losartan 50 mg,
bisoprolol 5 mg, hydrochlorothiazide 25 mg, and amlodipine 5 mg daily, each as a monother-
apy in randomized order for 4 weeks. These drug treatment periods were preceded and sepa-
rated from each other by 4 week placebo periods. Twenty four hour ambulatory blood
pressure (ABP) readings were recorded at the end of each treatment period with a device
equipped with a QRS complex detector and a position sensor (Diasys Integra; Novacor, Rueil
Malmaison, France); in addition, office blood pressure measurements were carried out with
repeated measurements after a 30 minute rest in the sitting position using a semiautomatic
oscillometric device. The performance and quality control of ABP recordings have been
described in detail earlier [23]. In short, readings were taken every 15 (standing) or every 30
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min (recumbent). Single observations were excluded due to low pulse pressure, high heart
rates, lying down during daytime, standing or being awake during night-time, or high physical
activity [23]. A total of15 daytime and 7 night-time readings were required for a recording
to be accepted. The present study utilizes ABP response data for the 4 different monotherapies.
The study was completed in altogether 228 men.
Blood plasma samples (collected in the morning under non-fasting conditions and stored
at -80˚C without any incidental thawings) for metabolite assays were available from 44 subjects
in the following way: amlodipine, 38 samples; bisoprolol, 41 samples; hydrochlorothiazide, 39
samples; and losartan, 42 samples. The mean metabolite levels of 3 samples from the interven-
ing placebo periods were used as baseline values in calculation of the drug effects; samples for
only 2 placebo periods were available for one patient and for 1 placebo period for five patients.
ABP recordings were evaluated in a fully blinded way as described earlier [23]; accepted
recordings were available for 38 patients after placebo treatment and for 32–38 patients after
each drug treatment.
The clinical part of the GENRES study was conducted in accordance with the Declaration
of Helsinki and Guidelines for Good Clinical Practice (1996) at Helsinki University Central
Hospital between years 1999 and 2004. The study was approved by the Ethical Committee of
Helsinki University Central Hospital and the National Agency for Medicines of Finland. All
subjects gave signed informed consent before any study related activities. The study is regis-
tered at ClinicalTrials.gov (NCT03276598).
Identification and measurement of plasma metabolites
EDTA-anticoagulated plasma samples were stored at -80˚C until processed. Sample processing
was carried out as described previously [25] at Metabolon, Inc. Briefly, recovery standards
were added prior to the first step in the extraction process for quality control purposes. Pro-
teins were precipitated with methanol under vigorous shaking for 2 min (Glen Mills Geno-
Grinder 2000) followed by centrifugation. The resulting extract was divided into five fractions
for analysis by ultra high performance liquid chromatography-tandem mass spectrometry
(UPLC-MS/MS), as outlined below.
Three types of controls were analyzed in concert with the experimental samples: first, sam-
ples generated from a pool of human plasma extensively characterized by Metabolon, Inc.
served as technical replicate throughout the data set; second, extracted water samples served as
process blanks; and third, a cocktail of standards spiked into every analyzed sample allowed
instrument performance monitoring. Instrument variability was determined by calculating the
median relative standard deviation (RSD) for the standards that were added to each sample
prior to injection into the mass spectrometers (median RSD = 5%; n = 31 standards). Overall
process variability was determined by calculating the median RSD for all endogenous metabo-
lites (i.e., non-instrument standards) present in 100% of the pooled human plasma matrix
samples (median RSD = 9%; n = 485 metabolites).
Non-targeted MS (mass spectrometry) analysis was performed at Metabolon, Inc. Extracts
were subjected to UPLC-MS/MS [25]. All methods utilized a Waters ACQUITY UPLC and a
Thermo Scientific Q-Exactive high resolution/accurate mass spectrometer interfaced with a
heated electrospray ionization source and Orbitrap mass analyzer operated at 35,000 mass res-
olution. The sample extract was vacuum dried then reconstituted in solvents compatible to
each of the four methods. Each reconstitution solvent contained a series of standards at fixed
concentrations to ensure injection and chromatographic consistency. One aliquot was ana-
lyzed using acidic positive ion conditions, chromatographically optimized for more hydro-
philic compounds. In this method, the extract was gradient-eluted from a C18 column
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(Waters UPLC BEH C18-2.1x100 mm, 1.7 μm) using water and methanol, containing 0.05%
perfluoropentanoic acid and 0.1% formic acid. The second aliquot was also analyzed using
acidic positive ion conditions; however, it was chromatographically optimized for more hydro-
phobic compounds. In this method, the extract was gradient eluted from the same aforemen-
tioned C18 column using methanol, acetonitrile, water, 0.05% perfluoropentanoic acid and
0.01% formic acid and was operated at an overall higher organic content. The third aliquot
was analyzed using basic negative ion-optimized conditions using a separate dedicated C18
column. The basic extracts were gradient eluted from the column using methanol and water,
however with 6.5mM ammonium bicarbonate at pH 8. The fourth aliquot was analyzed via
negative ionization following elution from a HILIC column (Waters UPLC BEH Amide
2.1x150 mm, 1.7 μm) using a gradient consisting of water and acetonitrile with 10mM ammo-
nium formate, pH 10.8. The fifth aliquot was reserved for backup. The MS analysis alternated
between MS and data-dependent MSn scans using dynamic exclusion. The scan range varied
slightly between methods but covered 70–1000 m/z.
Metabolites were identified by automated comparison of the ion features in the experimental
samples to a reference library of chemical standard entries that included retention time, molec-
ular weight (m/z), preferred adducts, and in-source fragments as well as associated MS spectra
and curated by visual inspection for quality control using software developed at Metabolon
[26,27]. Identification of known chemical entities is based on comparison to metabolomic
library entries of purified standards. Commercially available purified standard compounds have
been acquired and registered into LIMS for distribution to the various UPLC-MS/MS platforms
for determination of their detectable characteristics. Peaks were quantified using area-under-
the-curve. Raw area counts for each metabolite in each sample were normalized to correct for
variation resulting from instrument inter-day tuning differences by the median value for each
run-day, therefore, setting the medians to 1.0 for each run. This preserved variation between
samples but allowed metabolites of widely different raw peak areas to be compared on a similar
graphical scale. Missing values were imputed with the observed minimum after normalization.
Statistical analyses
Statistical analyses were done using IBM SPSS Statistics (v22). In these analyses, plasma metab-
olite levels were expressed as relative units: median of all analyzed samples was set to 1. In all
analyses, the mean of three placebo periods was used as the metabolite baseline level.
The changes in metabolite concentrations caused by study drugs are expressed as percent
change from baseline (mean of three placebo periods), and their statistical significance was
analyzed using Wilcoxon signed-rank test.
Correlation between metabolite baseline levels and the antihypertensive effects of the four
study drugs was analyzed using Pearson correlation. The residuals of normalized baseline
metabolite levels (means of three placebo periods) were used here. They were calculated using
stepwise regression with inclusion criterion of P < 0.10, and the tested covariates were age,
body mass index, current smoking, and serum creatinine, serum glucose and daily urinary
sodium excretion assessed after the first placebo period. Normalized baseline metabolite levels
were used if there were no significant covariates. The antihypertensive responses of the study
drugs were defined as the change in 24-hour ABP; means of all (up to four) placebo periods
were used as the baseline levels. The effect of baseline covariates on the ABP responses was
adjusted for by calculating residuals of systolic and diastolic ABP changes using stepwise
regression with inclusion criterion of P< 0.10. The tested covariates were corresponding base-
line ABP, age, current smoking, body mass index, daily urinary sodium excretion after the first
placebo period, and serum creatinine, cholesterol, HDL cholesterol and triglyceride levels after
Metabolomics of antihypertensive drugs
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the first placebo period. In addition to the corresponding (systolic or diastolic) baseline ABP
level, the selected covariates were: for amlodipine systolic ABP response, age, daily urinary
sodium excretion and serum cholesterol; for amlodipine diastolic ABP response, age, body mass
index, daily urinary sodium excretion and serum cholesterol; for bisoprolol systolic ABP
response, current smoking and serum cholesterol; for bisoprolol diastolic ABP response, no
other covariates; for hydrochlorothiazide systolic ABP response, age, daily urinary sodium excre-
tion and serum triglycerides; for hydrochlorothiazide diastolic ABP response, age and daily uri-
nary sodium excretion; for losartan systolic and diastolic ABP responses, serum creatinine.
Correlation between the antihypertensive responses of the four drugs and changes in
plasma metabolite levels was analyzed using partial correlation. Normalized value of the
plasma metabolite change caused by the drug and the residual of ABP response (described
above) were used. Normalized value of metabolite baseline level was used as the control
variable.
Considering the >600 metabolites studied and concentration changes caused by 4 different
drugs, a statistically significant change would require a P value of 2 x 10−5 (Bonferroni correc-
tion: 0.05/2400). However, we would consider even higher P values as potentially significant,
provided there were metabolites which represent common pathways and/or belong to a similar
biochemical family and which showed similar changes in response to a given drug. We used
the same criteria in assessment of the correlation of blood pressure responses with placebo
metabolite levels and changes in metabolite levels caused by the study drugs.
Results
General principles of data analysis
The dataset comprises 617 compounds of known identity that were measured in plasma sam-
ples of approximately 40 individuals after 1-month treatment of amlodipine (5 mg daily), biso-
prolol (5 mg daily), hydrochlorothiazide (25 mg daily) and losartan (50 mg daily), each as a
monotherapy in a rotational double-blind fashion, and after the preceding and intervening
1-month placebo periods (the average values of three placebo periods were used as the baseline
reference). The baseline characteristics and antihypertensive drug responses of the study sub-
jects are listed in Table 1.
The test panel included amino acids and peptides (171 biochemicals), carbohydrates (20
biochemicals), energy/tricarboxylic acid cycle (TCA) metabolites (8 biochemicals), lipids (260
biochemicals), nucleotides (27 biochemicals), vitamins and cofactors (25 biochemicals) and
xenobiotics (106 biochemicals) (S1 Table). Wilcoxon signed-rank test was used to identify
changes in biochemical levels showing statistical significance; the results are listed in S1 Table.
We carried out a detailed analysis to investigate first, individual drug effects on the different
metabolite levels, second, the correlation of the average placebo levels of the metabolites to the
blood pressure–lowering effects of the individual drugs, and third, the correlation between the
drug-induced change (increase or decrease) of a given metabolite to the corresponding drug-
induced change in blood pressure. In the latter two analyses, we used separately systolic and
diastolic ambulatory blood pressure values.
Effect of the four antihypertensive drugs on the levels of specific plasma
metabolites
Amlodipine administration caused a notably consistent decrease of plasma levels of acylcarni-
tines (P values down to 0.001), without affecting the level of the parent compound (carnitine)
itself (Fig 1). Likewise, bisoprolol therapy decreased the longer forms of acylcarnitines (P
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values down to 2 x 10−5), while this negative effect was less pronounced on acylcarnitines with
shorter fatty acid chains (Fig 1). Furthermore, bisoprolol tended to decrease plasma levels of a
number of long-chain fatty acids, including myristoleate, palmitoleate, oleate, eicosenoate and
linoleate (with P values 0.003 to 0.02, Fig 2), as well as plasma phosphate (P = 6 x 10−5) (S1
Table).
In contrast, hydrochlorothiazide therapy did not result in marked alterations of plasma
long-chain acylcarnitine levels, but slightly increased plasma carnitine (P = 4 x 10−5), propio-
nylcarnitine (P = 0.03) and butyrylcarnitine (P = 0.004) levels (Fig 1). In addition, this thiazide
diuretic tended to increase the urea cycle metabolites urea and citrulline but not ornithine and
arginine (S1 Fig). Homocitrulline, a urea cycle-related amino acid, was increased by hydro-
chlorothiazide (P = 0.01) and decreased by amlodipine (P = 9 x 10−4) in the absence of signifi-
cant effects on plasma creatinine levels (S1 Table). Furthermore, hydrochlorothiazide therapy
brought about a relatively consistent increase of several androgenic steroid sulfates, which was
paralleled by an increase in plasma inorganic sulfate level (S2 Fig). Not unexpectedly, thiazide
therapy caused a 13% increase of plasma uric acid level (P = 5 x 10−4), without markedly affect-
ing the levels of uric acid precursor compounds hypoxanthine and xanthine (Fig 3).
Similar to the effects of bisoprolol and amlodipine, losartan administration caused a
decrease in the circulating levels of medium- and long-chain acylcarnitines (P values down to
2 x 10−4) (Fig 1).
Table 1. Characteristics of the study subjects.
Number of study subjects 44
Age, y 48.9 ± 6.7
Body mass index, kg/m2 27.3 ± 2.9
Fasting serum glucose*, mmol/L 5.1 ± 0.6
Serum creatinine*, μmol/L 91.4 ± 9.5
Urinary excretion of sodium*, mmol/24 h 160 ± 59
Blood pressure during placebo periods, mmHg
Systolic ABP (n = 43) 134 ± 10
Diastolic ABP (n = 43) 92 ± 7
Systolic OBP (n = 44) 150 ± 12
Diastolic OBP (n = 44) 100 ± 7
ABP responses, mmHg
Amlodipine, systolic (n = 37) -5.9 ± 6.9
Amlodipine, diastolic (n = 37) -4.4 ± 3.4
Bisoprolol, systolic (n = 38) -10.2 ± 6.7
Bisoprolol, diastolic (n = 38) -7.7 ± 4.6
Hydrochlorothiazide, systolic (n = 36) -5.5 ± 6.0
Hydrochlorothiazide, diastolic (n = 36) -2.2 ± 4.0
Losartan, systolic (n = 32) -8.0 ± 5.9
Losartan, diastolic (n = 32) -5.6 ± 3.7
Data are presented as mean±SD.
*Fasting serum glucose and creatinine, and daily urinary sodium excretion values are from clinical
laboratory analyses after the first placebo period of the study. ABP, 24-hour ambulatory blood pressure;
OBP, office blood pressure.
https://doi.org/10.1371/journal.pone.0187729.t001
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Fig 1. Effect of antihypertensive drugs on selected plasma acylcarnitines. Plasma metabolite level is presented as relative units: the median of
all analyzed samples was set to 1. Box-and-whisker plots are presented. P values <0.05 from Wilcoxon signed-rank test are included. P, placebo
(mean of three periods); A, amlodipine; B, bisoprolol; H, hydrochlorothiazide; L, losartan.
https://doi.org/10.1371/journal.pone.0187729.g001
Metabolomics of antihypertensive drugs
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Baseline metabolite levels and antihypertensive responses of the four
drugs
In search for possible predictive biomarkers for a favorable antihypertensive effect, we corre-
lated the individual baseline metabolite levels (mean values of the placebo periods for a given
subject) to the corresponding systolic and diastolic responses, analyzed separately for each of
the four types of monotherapy. While we did not record correlations reaching P values< 2 x
10−5, we observed a trend for higher plasma levels of a number of aromatic amino acids (includ-
ing phenylpyruvate, phenylalanine and N-acetylphenylalanine) to predict better antihyperten-
sive responses to bisoprolol (with r values -0.48 to -0.31, and P values 0.002 to 0.06), and lower
levels of plasma serotonin and phosphoethanolamine to predict a better systolic response to
amlodipine (with r values 0.50 and 0.48, and P values 0.002 and 0.003, respectively). Calcula-
tions of correlations between baseline metabolite levels to hydrochlorothiazide or losartan
responses mostly yielded less significant data.
The correlation between the antihypertensive responses of the four
drugs and changes in the plasma levels of the metabolites
When amlodipine effects were studied and both systolic and diastolic blood pressure responses
were noted, the most consistent effects were noted for two metabolites: decreases of systolic
and diastolic blood pressure were associated with a decrease of plasma cysteinylglycine
(P = 0.0004 and 0.001, respectively) and, to somewhat lesser extent, of hexadecanedioate
Fig 2. Effect of antihypertensive drugs on selected plasma long-chain fatty acids. Plasma metabolite level is presented as relative units: the
median of all analyzed samples was set to 1. Box-and-whisker plots are presented. P values <0.05 from Wilcoxon signed-rank test are included. P,
placebo (mean of three periods); A, amlodipine; B, bisoprolol; H, hydrochlorothiazide; L, losartan.
https://doi.org/10.1371/journal.pone.0187729.g002
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(P = 0.06 and 0.04, respectively) levels (Fig 4). The relationships between other organic dicar-
boxylic acids and amlodipine effects were less marked.
In the case of bisoprolol, the most significant correlation emerged between systolic
(P = 0.02) and diastolic (P = 0.005) blood pressure lowering vs. decrease in plasma fructose
level (S3 Fig).
When a similar analysis of metabolite changes upon hydrochlorothiazide therapy was con-
ducted, less significant correlations to both systolic and diastolic blood pressure responses
were observed. On the other hand, calculations of relations between losartan-induced blood
pressure responses and metabolite level changes revealed correlations between lowering of sys-
tolic and diastolic blood pressure vs. decrease in plasma oleamide (P = 0.004 and 0.02, respec-
tively) and linoleamide (P = 0.004 and 0.03, respectively) (S4 Fig).
Discussion
Even though numerous antihypertensive drugs are available for treatment of essential hyper-
tension, many patients do not achieve proper control [3,4]. Currently, there is a lack of a set of
predictive biomarkers to help determine which anti-hypertensive drug mechanism and which
drug itself may be best suited for a given individual. This study examined plasma metabolites
in individuals treated with four different anti-hypertensive drugs relative to placebo controls.
The tested drugs were typical and widely used representatives of four major classes of blood
pressure-lowering agents: hydrochlorothiazide (diuretic); amlodipine (Ca+2 channel blocker);
bisoprolol (beta blocker) and losartan (angiotensin II receptor antagonist). The GENRES
study has a cross-over design with subjects being treated with all four drugs, each as a
Fig 3. Effect of antihypertensive drugs on uric acid and its precursors. Plasma metabolite level is
presented as relative units: the median of all analyzed samples was set to 1. Box-and-whisker plots are
presented. P values <0.05 from Wilcoxon signed-rank test are included. P, placebo (mean of three periods);
A, amlodipine; B, bisoprolol; H, hydrochlorothiazide; L, losartan.
https://doi.org/10.1371/journal.pone.0187729.g003
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monotherapy, and placebo wash-out periods occurred between treatments with the different
drugs. Placebo comparisons were conducted using an averaged placebo value composed of
three placebo plasmas collected from an individual subject.
In general, the magnitude of metabolite differences between drug-treated and placebo plas-
mas was relatively small. However, long- and medium-chain acylcarnitines were found to be
lower in most drug-treatment groups relative to placebo periods, except for hydrochlorothia-
zide, which resulted in marginal decreases only (Fig 1). The homeostasis of L-carnitine and its
esters is maintained in a careful and narrow fashion in the human body (for review, see [28]).
Carnitine moieties are added to fatty acids to facilitate transport across the mitochondrial
membrane for fatty acid β-oxidation. Decreases in long- and medium-chain acylcarnitines
such as palmitoylcarnitine and hexanoylcarnitine can represent a decreased level of fatty acid
β-oxidation, since acylcarnitine formation is a rate-limiting step in β-oxidation. Most mea-
sured long- and medium-chain acylcarnitines were lower in drug-treated relative to placebo
plasmas for each of the drugs. Interestingly, the short-chain acylcarnitines butyrylcarnitine
and propionylcarnitine tended to increase in all but the amlodipine plasmas, which runs
counter to the directional change of the long- and medium-chain acylcarnitines. Increased cir-
culating levels of acylcarnitines, particularly long-chain acylcarnitines, have been previously
linked to increased risk to predict cardiovascular events in patients at risk for coronary heart
disease [29–31]. The potential association of carnitine metabolism to development and treat-
ment of hypertension appears to be complex. Mostly based on studies in laboratory animals,
L-carnitine itself has been proposed as a protective agent against cardiac and renal remodeling
Fig 4. Correlation of the change of plasma cysteinylglycine and hexadecanedioate levels with the
antihypertensive effect of amlodipine. Correlation coefficients (r) and P values from partial correlation,
calculated with normalized metabolite change values and controlling for metabolite baseline level, are
included. dASBP, change of 24-hour ambulatory systolic blood pressure; dADBP, change of 24-hour
ambulatory diastolic blood pressure.
https://doi.org/10.1371/journal.pone.0187729.g004
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in arterial hypertension [32]. However, both serum L-carnitine and long-chain acylcarnitine
levels were reported to be positively correlated to ambulatory blood pressure [33], and
increased plasma carnitine as well as short- and long-chain acylcarnitine levels were measured
in in patients with preeclampsia [34]. Increased long-chain acylcarnitine levels have also been
associated with insulin resistance with diabetes, possibly via interference of insulin signaling
within the cell membrane, while this relation is less clear for short-chain acylcarnitines [35].
Provided it is especially the long-chain acylcarnitines that may be associated with adverse car-
diometabolic effects, it is of some interest that in our study the thiazide diuretic, known to
induce insulin resistance, did not markedly reduce plasma long-chain acylcarnitines.
Short-chain acylcarnitines can also be generated from branched-chain amino acid metabo-
lism and may not be completely reflective of generation from fatty acid β-oxidation. If increased
fatty acid β-oxidation or decreased TCA cycle activity leads to an excess of acetyl-CoA, ketogen-
esis can occur resulting in the formation of ketone bodies such as 3-hydroxybutyrate (BHBA).
Similarly, a reduction in acetyl-CoA concentration may lower ketogenesis and BHBA levels.
BHBA levels were 17% lower in plasma samples after bisoprolol treatment compared with aver-
aged placebos (P = 0.007) (S1 Table).
A group of sulfated steroids were elevated after hydrochlorothiazide administration (S2
Fig). The significance of this finding remains obscure, as sulfated steroids as such are proposed
to act as a steroid reservoir in blood plasma, with no ability as hydrophilic molecules to pene-
trate target cell membrane and to interact with steroid receptors [36,37]. The most abundant
sulfated steroid dehydroepiandrosterone sulfate may have impact on blood pressure regula-
tion, but its levels were not significantly affected by the four drugs tested in the present study
(S2 Fig).
Hydrochlorothiazide and amlodipine induced interesting and partially diverse effects on
urea cycle-related metabolites (S1 Fig). Citrulline, an intermediate of urea biosynthesis, and
urea were elevated upon hydrochlorothiazide administration (S1 Fig, S1 Table). Similar find-
ings were published as early as in 1969 for urea [38]. There appears to be no such data for cit-
rulline. Urea cycle function is of interest regarding hypertension because of the production of
the vasoactive compound nitric oxide from arginine and homoarginine. However, these two
precursor amino acids were not altered by thiazide therapy. Homocitrulline (ε-carbamoyl
lysine) may be generated in vivo through a pathway involving decomposition of urea to ammo-
niac and cyanate. Cyanate in turn is rapidly converted to a highly reactive isocyanic acid,
which then reacts with the ε-amino group of lysine, forming homocitrulline. It may also be
produced at sites of inflammation through the action of myeloperoxidase [39]. Therefore,
homocitrulline may serve as a marker of protein carbamoylation, which may affect the func-
tion of proteins and mediate, e.g. some of the deleterious effects of uremia [40]. Elevated
plasma protein-bound homocitrulline concentrations predict increased risk of coronary artery
disease, future myocardial infarction, stroke and death [39], and elevated free serum homoci-
trulline concentration is associated with poor coronary collateral growth in coronary heart dis-
ease patients [41]. However, it remains unclear whether reduction of homocitrulline levels by
amlodipine (median change -21%, P = 9 x 10−4) and elevation of its levels by hydrochlorothia-
zide (median change +16%, P = 0.004) have any relation to risk reduction of cardiovascular
events during antihypertensive treatment.
The search for possible predictive baseline metabolic markers for antihypertensive drug
responsiveness turned out to result in somewhat disappointing data. No metabolite in placebo
plasma samples was shown to associate with an antihypertensive drug response at statistical
significance level of P< 2 x 10−5. The potential association of baseline levels of aromatic
amino acids, phenylalanine and N-acetylphenylalanine in particular, as already reported by us
[42], to a favorable response to bisoprolol is of some interest due to our previous findings of
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association between ACY3 (coding for aminoacylase 3) variation and bisoprolol responsive-
ness [13]; aminoacylase 3 is the enzyme catalyzing conversion of N-acetylphenylalanine to
phenylalanine. It is of note that while the levels of a number of long-chain acylcarnitines were
diminished in a relatively systematic fashion by amlodipine, bisoprolol and losartan, their
baseline levels were not predictive for a good antihypertensive response to any of these drugs.
The fact that both systolic and diastolic blood pressure responses to amlodipine treatment
were correlated to decreases in plasma hexadecanedioate concentration (Fig 4) is intriguing
due to recent data by Menni et al. [21], linking this metabolite to blood pressure regulation.
Indeed, circulating hexadecanedioate showed association with systolic and diastolic blood
pressure levels in three different patient cohorts (TwinsUK, KORA and Hertfordshire, alto-
gether appr. 8 000 individuals) and was also associated with mortality in TwinsUK sample.
Furthermore, administration of hexadecanedioate to Wistar-Kyoto rats was demonstrated to
increase blood hexadecanedioate as well as blood pressure. These authors also showed that this
metabolite increased vascular reactivity to noradrenaline in these animals [21]. Considering
the marked changes of plasma acylcarnitines induced by amlodipine in the present study (Fig
1), it is of interest that Menni et al. [21] also observed an inverse correlation between plasma
hexadecanedioate and carnitine levels. More recently, elevated levels of hexadecanedioate were
associated with increased blood pressure levels and risk of incident heart failure in both Afri-
can-Americans and an independent sample of European Americans [22]. Collectively, all these
data tend to link fatty acid transport and oxidation mechanisms to blood pressure regulation
and, possibly, to the antihypertensive action of some antihypertensive drugs including
amlodipine.
There are only scant previous systematic studies on blood pharmacometabolomics in
human hypertension. The PEAR investigators reported certain racial differences in blood
metabolite profile following antihypertensive drug administration and found that the levels of
a number of organic acids, including oleic, linoleic, palmitoleic, palmitic, BHBA and myristic
acid, were significantly decreased upon atenolol treatment of white and, to slightly lesser
extent, of black patients [18]. Interestingly, we could replicate all of the latter findings in our
study using bisoprolol as our beta blocker (Fig 2), thus further supporting the idea that fatty
acid metabolism may have important role in blood pressure control by antihypertensive
agents. Due to marked differences in the metabolite panel assayed by us and that by the PEAR
Study group [19,20], it is not possible to systematically compare the metabolite signatures after
thiazide treatment in these two studies. However, we found a general increase of the urea cycle
metabolites after hydrochlorothiazide administration, which appears to be in line with the data
of the PEAR group [19]. In contrast to the data of Rotroff et al. [19], we did not see marked dif-
ferences in plasma levels palmitoleic and arachidonic acid upon thiazide treatment.
There are important limitations of the study. First of all, metabolite analyses were con-
ducted in only 44 individuals, which may increase the probability of chance findings. It should
be emphasized, however, that variation in the baseline levels could be significantly diminished
by using the means of three placebo values. Even if a replication study following the exact
design of the GENRES Study would be heavy to be conducted, we emphasize the need for rep-
lication reports coming e.g. from data bases of previously conducted studies where data on
specific antihypertensive drugs and specific metabolites would be available. Second, the sub-
jects were not asked to fast during sample collection, which may increase metabolite variability
in plasma. We chose this policy intentionally, in order to avoid unavoidable and undesirable
stress which could have affected the ongoing ABP and office BP measurements. Third, the
GENRES Study was designed to involve male hypertensive patients only. The strengths of our
study include its rotational design as well as the wide spectrum of biochemicals analyzed,
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which both should facilitate detection of overall differences in metabolic signatures caused by
different classes of antihypertensive agents.
In conclusion, treatment of male subjects with four antihypertensive medications, each
with different mechanisms of action, resulted in subtle changes to their plasma metabolite pro-
files, relative to placebo controls. The most generalized metabolite response to anti-hyperten-
sive treatment was a decline in the levels of acylcarnitines, in particular by a calcium channel
and a beta blocker, indicative of a change in fatty acid metabolism. Another finding of special
note was the association of the antihypertensive effect of amlodipine to the decline in plasma
hexadecanedioate, a metabolite recently strongly associated with blood pressure regulation.
Overall, our data indicate that treatment with anti-hypertensive agents result in limited
changes to plasma metabolite profiles. Some metabolite changes more prominent to specific
drugs may offer some insights into how different mechanisms of action impact plasma metab-
olite homeostasis.
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